Sökning: onr:"swepub:oai:DiVA.org:uu-342674" >
Neuroendocrine tumo...
Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion : a retrospective study
-
- Antonodimitrakis, Pantelis Clewemar (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Olofsson, Helena (författare)
- Uppsala universitet,Klinisk och experimentell patologi
-
- Grimelius, Lars (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
visa fler...
-
- Sundin, Anders, 1954- (författare)
- Uppsala universitet,Radiologi
-
- Wassberg, Cecilia (författare)
- Uppsala universitet,Radiologi
-
- Granberg, Dan (författare)
- Uppsala universitet,Onkologisk endokrinologi
-
- Skogseid, Britt (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Eriksson, Barbro (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
visa färre...
-
(creator_code:org_t)
- Future Medicine Ltd, 2017
- 2017
- Engelska.
-
Ingår i: International Journal of Endocrine Oncology. - : Future Medicine Ltd. - 2045-0869 .- 2045-0877. ; 4:1, s. 9-22
- Relaterad länk:
-
https://www.futureme...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aim: Vasoactive intestinal polypeptide producing neuroendocrine tumors are rare and cause severe hormonal symptoms. Patients/methods: Eighteen patients with vasoactive intestinal polypeptide producing neuroendocrine tumors were analyzed with reviews of medical records, radiology and tumor tissue specimens. Results: Twelve patients (67%) had liver metastases at diagnosis. Chemotherapy, somatostatin analogs and interferon were given as medical therapies. Streptozocin/5-fluorouracil produced an objective response in 40% of the evaluable patients. Somatostatin analogs gave a clinical/biochemical response in eight out of nine patients. Transarterial embolization of the liver and peptide receptor radionuclide therapy was given to refractory cases. Sixteen patients died during the observation period. The median overall survival from diagnosis was 102 months. Conclusion: Systemic chemotherapy and somatostatin analogs should be given in cases of advanced disease or for hormonal symptoms.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- chemotherapy
- IFN-α
- neuroendocrine tumors
- pancreas
- somatostatin analogs
- survival
- vasoactive intestinal polypeptide
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas